Trial · NCT01218516
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival (PFS) | Combination Therapy: Placebo + Chemotherapy | Per Primary Analysis Cut-Off Date | 5.8 | 95% Confidence Interval 5.0 to 6.8 | Months |
| Progression-free Survival (PFS) | Combination Therapy: Farletuzumab + Chemotherapy | Per Primary Analysis Cut-Off Date | 4.7 | 95% Confidence Interval 4.2 to 5.6 | Months |
| Progression-free Survival (PFS) | Combination Therapy: Placebo + Chemotherapy | Per Final Analysis Cut-Off Date | 5.9 | 95% Confidence Interval 5.0 to 7.0 | Months |
| Progression-free Survival (PFS) | Combination Therapy: Farletuzumab + Chemotherapy | Per Final Analysis Cut-Off Date | 4.7 | 95% Confidence Interval 4.2 to 5.6 | Months |
| Overall Response Rate (ORR) | Combination Therapy: Placebo + Chemotherapy | 37.3 | Percentage of participants | ||
| Overall Response Rate (ORR) | Combination Therapy: Farletuzumab + Chemotherapy | 41.3 | Percentage of participants | ||
| Duration of Response (DR) | Combination Therapy: Placebo + Chemotherapy | 6.7 | 95% Confidence Interval 4.1 to 9.4 | Months | |
| Duration of Response (DR) | Combination Therapy: Farletuzumab + Chemotherapy | 4.1 | 95% Confidence Interval 3.0 to 7.0 | Months | |
| Overall Survival (OS) | Combination Therapy: Placebo + Chemotherapy | 10.5 | 95% Confidence Interval 8.3 to 14.0 | Months | |
| Overall Survival (OS) | Combination Therapy: Farletuzumab + Chemotherapy | 14.1 | 95% Confidence Interval 9.5 to 18.6 | Months | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs) | Combination Therapy: Placebo + Chemotherapy | TEAEs | 60 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs) | Combination Therapy: Farletuzumab + Chemotherapy | TEAEs | 63 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs) | Monotherapy: Placebo | TEAEs | 30 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs) | Monotherapy: Farletuzumab | TEAEs | 25 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs) | Combination Therapy: Placebo + Chemotherapy | Treatment emergent SAEs | 27 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs) | Combination Therapy: Farletuzumab + Chemotherapy | Treatment emergent SAEs | 27 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs) | Monotherapy: Placebo | Treatment emergent SAEs | 6 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs) | Monotherapy: Farletuzumab | Treatment emergent SAEs | 7 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01218516/results